Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerGalina Semenova(University of California, Los Angeles), John K. Lee(APLA Health)bioRxiv (Cold Spring Harbor Laboratory)September 11, 202510.1101/2025.09.05.674562Cited by 0SaveCiteExport RISWatch citationsRelated PapersN-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells|Cancer Cell|2016|416Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy|Nature Communications|2023|118